Human plasma obtained from patients with hypomegakaryocytic thrombocytopenia contains a factor that promotes megakaryocyte colony formation by normal human marrow cells. This megakaryocyte colony-stimulating factor was purified from such a plasma specimen. A four-step purification scheme which included ammonium sulfate precipitation, diethylaminoethylSepharose chromatography, affinity chromatography on wheat germ lectin-Sepharose 6MB, and reverse-phase high performance liquid chromatography resulted in a recovery of 16.6% of the initial biological activity and an increase in specific activity by 3,489-fold. The purified protein produced a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Purified megakaryocyte colony-stimulating factor was capable of promoting megakaryocyte colony formation at a concentration of 7.6 X iO-M. Megakaryocyte colony-stimulating factor was shown to be a glycoprotein and had an apparent 46,000 mol wt. Deglycosylation of megakaryocyte colony-stimulating factor by treatment with trifluoromethanesulfonate resulted in the loss of its ability to promote megakaryocyte colony formation. Megakaryocyte colony-stimulating factor appears to be an important regulator of in vitro human megakaryocytopoiesis at the level of the colony-forming unit megakaryocyte and may be of importance physiologically.
Introduction
Megakaryocytopoiesis appears to be regulated by two factors that specifically affect the proliferation of progenitor cells and the development of megakaryocytes in vitro (1, 2) . In this scheme, megakaryocyte colony-stimulating factor (Meg-CSF)' modulates the proliferation of the progenitor cell pool, whereas 1 . Abbreviations used in this paper: BFU-E, erythroid burst-forming unit; CFU-E, erythroid colony-forming unit; CFU-GM, granulocytemacrophage colony-forming unit; CFU-M, megakaryocyte colonyforming unit; Epo, erythropoietin; GM-CSA, granulocyte-macrophage colony-stimulating activity; Meg-CSF, megakaryocyte colony-stimulating factor; PAGE, polyacrylamide gel electrophoresis; PAS, periodic acidSchiff; PGP, (human) platelet glycoproteins; PHA-LCM, phytohemagglutinin-stimulated leukocyte-conditioned media; TFMSA, trifluoromethane sulfonate; TSF, thrombopoietic stimulating factor or thrombopoietin.
thrombopoietin influences megakaryocyte development (2) . Similar dual requirements for hematopoietic regulatory molecules have been described in the erythroid (3) and macrophage pathways (4) .
Urine (5, 6) , serum (7) , and plasma (8, 9) obtained from patients with hypomegakaryocytic thrombocytopenia have been shown to promote the formation of megakaryocyte colonies by marrow mononuclear cells in vitro. Phytohemagglutininstimulated leukobyte-conditioned media as well as normal bone and lung conditioned media contain a similar activity (10). Recently Messner et al. (8) have suggested that human plasma is superior to serum in its ability to support megakaryocyte colony formation in vitro. Kimura et al. (9) have demonstrated that factors released from platelets during the clotting process inhibit megakaryocyte colony formation. Vainchenker et al. ( 1) also suggest that there are substances present in human serum which are essential for megakaryocyte colony formation, and that an additional factor is present which is capable of inhibiting colony formation. The exact role of this inhibitory substance in the regulation of human megakaryocytopoiesis is unclear.
Previous studies of in vitro megakaryocytopoiesis have utilized unfractionated conditioned media (8) , serum (7) , or plasma (8) as sources of Meg-CSF. In the present report, we describe the purification and partial characterization of Meg-CSF from human plasma. The availability of this purified molecule will help to delineate the complex cellular and molecular events that occur during human megakaryocytopoiesis.
Methods
Source ofMeg-CSF Meg-CSF was purified from plasma obtained from a 36-yr-old white woman with an acquired hematologic disorder characterized by macrocytosis (mean corpuscular volume, 124 fi), anemia (packed cell volume, 22%), mild leukopenia, and severe thrombocytopenia (platelet count <10,000 mm3). Bone marrow specimens obtained on several occasions were noted to be normocellular with megaloblastoid erythroid maturation and normal granulocyte development. The marrow specimens were most notable for a total absence of megakaryocytic elements. This clinical picture was compatible with a diagnosis of selective hypomegakaryocytic thrombocytopenia (12) . Because (15) was modified by the substitution of heat-inactivated human AB serum for fetal calf serum, and a-medium minus nucleosides for NCTC-109 medium and Eagle's minimal essential medium with Hanks' balanced salt solution. Samples to be assayed for Meg-CSF activity were diluted in a-medium minus nucleosides at several dilutions. The final 1-cm3 aliquot of each culture contained the following supplements: minimal essential medium, nonessential amino acids (0.02 mmol/ml), L-glutamine (0.4 mmol/ml), and sodium pyruvate (0.2 mmol/ml). Culture dishes were incubated for 10-12 d (unless otherwise stated) at 37°C in a 100% humidified atmosphere of 5% CO2 in air. Harvesting was performed by in situ fixation with methanol: acetone (1:3) for 20 min, washed with 0.01 M phosphate-buffered saline (PBS), pH 7.2, distilled water, and then air-dried. Plasma clots were stored frozen at -20°C until immunofluorescent staining was performed.
Preparation of antiplatelet glycoprotein antiserum
Antiplatelet glycoprotein antiserum was utilized to identify megakaryocyte colonies. Purified human platelet glycoprotein (PGP) was prepared by lithium diiodosalicylate-phenol extraction of pooled human platelet concentrates as described by Marchesi and Chasis (16) . New Zealand White rabbits were initially immunized by subcutaneous injections of 1 mg of PGP in Freund's complete adjuvant, followed by intramuscular injections (1 mg of PGP in Freund's incomplete adjuvant) at 2 and 4 wk. Serum was harvested at 6 wk by cardiac puncture and stored in aliquots at -80°C. The specificity of the rabbit anti-PGP antiserum has been previously established (17) . This antiserum has been found to precipitate 80% of radiolabeled lithium diiodosalicylateextracted PGP, but nonimmune rabbit serum precipitated only 15% of the radioactivity. Slab gel electrophoresis of immunoprecipitates corresponded to PGP of estimated mol wt of 145,000, 125,000, and 95,000, demonstrating activity of the antiserum for the original immunogen (17). When normal bone marrow smears were examined by using indirect immunofluorescent labeling, only platelets, megakaryocytes, and an infrequent population of lymphoidlike cells fluoresced intensively (17) . These lymphoidlike cells are thought to represent immature megakaryocytic elements. Preadsorption of the antiserum through a PGP-Sepharose affinity column has been reported to remove all platelet-and megakaryocyte-labeling activity (17 (19) . Maximum growth of CFU-E-and BFU-E-derived colonies in this modified plasma clot assay system was seen at Epo concentrations of 0.5 and 1.0 IU/ml, respectively.
The colony assay for granulocyte-macrophage colony-forming units (CFU-GM) was carried out according to the method of Fauser and Messner (20) . Marrow mononuclear cells were suspended in 35-mm Lux standard tissue culture dishes, containing a 1-ml mixture of Iscove's modified Dulbecco's medium (IMDM; Gibco Laboratories), 0.8% methylcellulose, 30% fetal bovine serum, 5% medium conditioned by leukocytes from patients with hemochromatosis in the presence of 1% phytohemagglutinin (PHA-LCM) (21), and 5 X l0-5 M 2-mercaptoethanol. Dishes were incubated at 37°C in a humidified atmosphere flushed with 5% CO2 in air. Colonies were scored with an inverted microscope after 13-14 d of incubation. Clusters of .40 cells, many of which had typical band or segmented polymorphonuclear leukocyte morphology were defined as CFU-GM-derived colonies.
Protein estimations
Protein was estimated by the method of Lowry et al. (22) using bovine serum albumin as a standard. The absorbance at 280 nm was used to monitor the relative protein concentrations of column effluents.
Purification of Meg-CSF
Ammonium sulfate fractionation. To 400 ml of plasma, (NH4)2SO4 (116.4 g; 50% saturation) was added with stirring. The solution was kept at 4°C for 30 min and then centrifuged at 27,000 g at 4°C for 20 min in a refrigerated centrifuge (J2-21 model, Beckman Instruments, Inc., Palo Alto, CA). The supernatant was decanted and the sediment was discarded. The supernatant was subsequently sequentially adjusted to 60, 70, and 80% saturation by the addition of (NH4)2SO4 while the mixture was stirred and the centrifugation cycle was repeated as described above. The sediments from each saturation level were resuspended in 0.15 M NaCi and dialyzed against 0.01 M K2HPO4 buffer, pH 7.4, containing 0.15 M NaCi for 24 h with three changes of the dialysate every 8 h. This was followed by two additional changes of the dialysate with distilled water at 12-h intervals at 4VC. These samples, which were the sediments produced by the 60, 70, and 80% (NH4)2SO4 fractionation steps were lyophilized and stored at -20'C. Each of these fractions was subsequently dissolved in a-media and assayed for Meg-CSF activity.
Ion exchange column chromatography. A C10/40 column (Pharmacia Fine Chemicals) was packed with DEAE-Sepharose CL-6B previously equilibrated with 0.05 M sodium acetate buffer, pH 5.4, containing 0.02% NaN3 (starting buffer). The lyophilized (NH4)2SO4 precipitates were individually dissolved in starting buffer and sequentially applied to the column at a flow rate of 15 ml/h. The column was subsequently eluted with the following elution buffers: (a) 0.05 M sodium acetate buffer, pH 5.4; (b) 0.05 M sodium acetate buffer containing 0.15 M NaCl; and (c) 0.05 M sodium acetate buffer containing I M NaCl, at a flow rate of 15 ml/h. 130 fractions (4 ml each) were collected. Column effluent was monitored with a Gilson absorbance monitor (Gilson Co., Inc., Worthington, OH) at A280 with chart recorder (Fig. 1 ). Fractions were pooled, dialyzed against sterile water, and tested for Meg-CSF activity. Active fractions were lyophilized and stored at -200C.
Wheat germ lectin affinity chromatography. Wheat germ lectin was coupled to Sepharose beads after cyanogen bromide activation as described by the method of March et al. (23). An active fraction (fraction V) obtained after ion exchange chromatography (Fig. 1 , Table  I ) was dissolved in 0.05 M Na2HPO4 buffer, pH 7.2 (PBS) containing 0.02% NaN3 and applied to a column (K9/15, Pharmacia Fine Chemicals), which was packed with cyanogen bromide-activated wheat germ lectin-Sepharose beads. The column was preequilibrated and desorbed with PBS, pH 7.2, containing 0.2 M NaCl. Buffer was applied to the column by a peristaltic pump, the flow rate was adjusted to 25 ml/h, and 1.5-ml fractions were collected. Protein in the column effluent was monitored by a Gilson absorbance monitor (Gilson Co., Inc.) at A280 with chart recorder. The column was washed with PBS until the effluent was free of protein. The column was subsequently batch eluted with 0.1 M N-acetyl-D-glucosamine (Fig. 2) . Column fractions were pooled according to the absorbance at A280 (Fig. 2) . Free sugar and salts were removed by gel filtration with a Bio-Gel P-6DG column (Bio-Rad Laboratories). Lyophilized active fractions were stored at -200C.
Reverse-phase high-performance liquid chromatography. The freezedried fraction (15 ug) from the wheat germ lectin-affinity chromatography step (Fig. 3) was dissolved in 30-10% H20/CH3CN. The mixture was injected onto a Whatman C18 ODS3 column (Whatman Inc., Clifton, NJ) (0.4 X 25 cm). The column was eluted at 0.5 ml/min with a linear gradient of 30-70% acetonitrile. The column effluent was monitored by absorbance at 270 nM and recorded. To remove acetonitrile, fractions were diluted with 3 vol of water and dried with a Savant Speed Vac concentrator (Savant Instruments, Inc., Hicksville, NY). These fractions were stored at -20°C.
Recovery ofbiologically active factor from SDS-polyacrylamide gel electrophoresis (PAGE) gel. Samples (2 ml) of concentrated fractions obtained following wheat germ lectin-Sepharose CL-6B chromatography were run on slab gels (3 X 140 X 110 mm3) together with standard molecular weight markers. At the end of the run the distance from the tracking dye to the top of the running gel was carefully measured. A strip of the gel was cut vertically for staining and the other part was retained for measurement of biological activity. The unstained part of the gel was sliced horizontally in 5-mm sections according to the position of bands on the stained gel. The gel slices were shaken overnight at 4°C in 10 ml of 0.02 sodium phosphate buffer, pH 7.2. The buffer solution was decanted and saved. This extraction step was repeated once and the gel slices then removed and discarded. These supernatants were combined and centrifuged to further remove gel particles and were then dialyzed against double-distilled water for 24 h with three changes of water, followed by ultrafiltration using an Amicon model 52 cell concentrator (Amicon Corp., Lexington, MA), lyophilized, and stored at -20°C until it was reconstituted in a-media for use in the biological assay. The strip part of the gel was fixed, washed, and stained as a template. When comparing the unstained portion of the gel with the biologically assayed portion, the gel swelling was taken into account.
PAGE. The partially purified fractions were analyzed by electrophoresis in the presence of SDS according to the method of Laemmli (24) (Fig. 4 (25, 26) . Deglycosylation by TFMSA. The partially purified material obtained after wheat germ lectin affinity chromatography was deglycosylated according to the method of Edge et al. (27) . Briefly, 1 ml of anisole and 2 ml of TFMSA were mixed in a glass tube with a screw cap and cooled to 0°C. The partially purified fraction (0.6 mg) was added to Figure 2 . Elution profile of human Meg-CSF from wheat germ-lectin Sepharose beads by N-acetyl-glucosamine. 60 mg of fraction V obtained by gel filtration column chromatography was applied in a vol of 2 ml to a 9 X 150-mm column of wheat germ lectinSepharose 6MB equilibrated with starting buffer (0.05 M phosphate buffer, pH 7.2, containing 0.2 M NaCl and 0.02% [wt/vol] NaN3). The column was eluted with starting buffer at a flow rate of 40 ml/h. Fractions were collected in 1.5 ml/tube and the absorbance at 280 mm was monitored. The this precooled mixture (0.6 ml) and the reaction was allowed to proceed at room temperature for 40 min. Then 6 ml of diethyl ether (precooled in frozen CO2) was added, followed by 1 ml of cold 50% (vol/vol) aqueous pyridine. The solution was centrifuged, after which the ether phase was removed with a pasteur pipette. This extraction procedure was repeated another time. The remaining aqueous-phase volumes were combined and diluted to total volume of 2 ml with water, and pyridine was removed by gel filtration on P-6DG column (Bio-Rad Laboratories) equilibrated with PBS. The void volume fractions were collected in a final volume of 5.6 ml and concentrated to dryness in a Speed Vac concentrator. The dried material was stored at -20'C before assay for Meg-CSF activity. At the time of assay the dried fractions were suspended in a-medium at various protein concentrations.
Results
Purification. When bone marrow cells are cloned in the absence of a source of Meg-CSF, 14.6±8.5 (mean±l SD) megakaryocyte colonies per 5 X 105 marrow cells plated were observed. This background colony formation was observed in each of the 10 normal marrow samples studied. After ammonium sulfate fractionation at 60% saturation, no Meg-CSA activity was detected in the precipitate. A small amount of activity was recovered in the 70% fraction (data not shown).
The greatest activity was recovered in the precipitate which formed at 80% saturation (Table I) . The elution profile resulting from DEAE-Sepharose CL-6B chromatography of the 80% (NH4)2SO4 fraction is shown in Fig. 1 . A significant amount of protein was eliminated in peaks II and III, which emerged before the active fractions, peaks IV, V, and VI. The most potent Meg-CSF activity resided in fraction V (Table I) .
Further purification of the protein responsible for megakaryocyte colony formation was achieved after wheat germ lectin-affinity chromatography (Fig. 2) . No activity was detected in the eluate desorbed with the starting buffer. In contrast, a highly purified fraction was obtained following batch elution of the column with N-acetyl-D-glucosamine (Table I) . Fig.'3 illustrates the elution profile as obtained from a Whatman C18 ODS3 column (Whatman, Inc., Clifton, NJ) by reverse-phase high performance liquid chromatography. The major peak of Meg-CSF activity coincided with the main peak of ultraviolet absorbing material. The highly purified material was capable of promoting the formation of 10,466 megakaryocyte colonies/mg of protein (Table I ). The four-step purification scheme resulted in the recovery of 16.6% of the assayable Meg-CSF present in the starting plasma specimen.
Apparent molecular weight. The molecular weight of Meg-CSF was determined by its relative migration in comparison to known molecular weight markers in SDS-polyacrylamide gels. Duplicate gels stained with Coomassie Blue and PAS are shown in Fig. 4 . The material that eluted off the wheat germ lectin-affinity column produced a single band whose staining characteristics were consistent with its being a glycoprotein with an apparent mol wt of 46,000 (Fig. 4) . The electrophoretic mobility of the purified Meg-CSF in SDS-PAGE under reduced and nonreduced conditions are identical. It is possible that the true molecular weight based on amino acid and carbohydrate analysis may be lower due to the aberrant migration of glycoproteins in SDS-polyacrylamide gels (25, 26) . The relative migration of purified Meg-CSF and a preparation of partially purified human urinary Epo in SDS-polyacrylamide gels is illustrated in Fig. 5 . As can be seen, based upon this parameter, Therefore the activity of a purified fraction was tested before and after the addition of TFMSA. Deglycosylation of Meg-CSF by this method abolished the ability of the purified fraction to promote megakaryocyte colony formation (Table II) .
Stimulation ofcolony formation by bone marrow cells. The effect of varying concentrations of purified Meg-CSF on megakaryocyte colony formation is shown in Fig. 6 . As can be seen in this figure, there appears initially to be a linear relationship between the dose of Meg-CSF and the number of colonies enumerated. At higher concentrations, however, the effect of Meg-CSF appears to reach a plateau. At a concentration of Figure 6 . Effect of varying concentrations of purified Meg-CSF on megakaryocyte colony formation by normal human marrow cell. Each point represents the mean of assays performed in quadruplicate.
7.6 X 10-8 M, the purified Meg-CSF was capable of promoting the formation of one-half of the maximal numbers of megakaryocyte colonies by normal bone marrow cells.
In Table III the specificity of the action of purified Meg-CSF is shown. The ability of Meg-CSF to promote CFU-Eand BFU-E-derived colonies is compared with that of a source of Epo, and its ability to promote CFU-GM-derived colonies is compared with a PHA-LCM with a known granulocytemacrophage colony-stimulating activity (GM-CSA). From this data it is evident that the purified Meg-CSF does not have the ability to promote CFU-GM, BFU-E-, or CFU-E-derived colony formation. In addition, in Table III it is shown that the 46,000 mol wt band when eluted from the SDS-PAGE retained 75% of its biological activity. This data further substantiates our contention that this glycoprotein is the putative Meg-CSF. We have previously suggested that Meg-CSF not only alters cloning efficiency of the colony-forming unit megakaryocyte (CFU-M) but that it also increases the number of cells composing megakaryocyte colonies (17). A similar phenomena was observed when CFU-M was cloned in the presence of purified Meg-CSF. We were able to enumerate the numbers of cells in 35 colonies cloned in the absence of Meg-CSF (9.5±3.1 megakaryocytes [mean± 1 SD]). By contrast, when 37 colonies cloned in the presence of purified Meg-CSF were analyzed, In the absence of a source of Meg-CSF, 35-75% of all the megakaryocyte colonies present consisted exclusively of the small fluorescein-labeled cells. We have previously reported that the addition of apiastic anemia sera resulted in a relative decrease in the numbers of the colonies composed exclusively of small fluorescein positive cells (14) . By contrast, the addition of purified Meg-CSF did not result in a similar increase in the numbers of colonies composed of morphologically identifiable megakaryocytes or a decrease in the numbers of colonies containing exclusively fluorescein positive small mononuclear cells.
Discussion
Factors that control human thrombopoiesis and megakaryocytopoiesis have not been well characterized (28) . Thrombopoieticstimulating factor (TSF) or thrombopoietin appears to accelerate thrombopoiesis in vivo. TSF has been detected in media conditioned by human embryonic kidney cells (29) and in plasma of thrombocytopenic humans and animals (30, 31) .
Recently, a number of in vitro clonal culture systems have been developed to analyze the early events in human megakaryocytopoiesis (7, 9) ; Meg-CSF activity has been detected in a variety of crude human body fluids including urine (5, 6), serum (7), and plasma from thrombocytopenic individuals (7, 8) . Meg-CSF not only increases cloning efficiency, but may also increase the proliferative capacity of individual CFU-M as evidenced by a statistically significant increase in the number of cells observed per colony (7) . The variations in Meg-CSF levels that have been detected in different disease states suggest that alterations in the production of this regulator are physiologically important (7) .
The availability of purified regulatory molecules and cell populations are a prerequisite for unraveling the complexities of human megakaryocytopoiesis. Such an approach has been extremely useful in the study of human and murine granulopoiesis and erythropoiesis (32, 33) where purification of Epo (32) , erythropoietic burst-promoting activity (34, 35), and various subclasses of GM-CSA (36-38) have provided a better understanding of both granulopoiesis and erythropoiesis.
We approached the purification of human Meg-CSF with a four-step scheme including ammonium sulfate fractionation, ion exchange column chromatography, wheat germ lectinaffinity chromatography and reverse-phase high performance liquid chromatography. The plasma clot culture system for human megakaryocyte colonies was utilized to assay for Meg-CSF activity (7 hematopoietic cells as well as megakaryocytic, erythroid, and granulocytic committed progenitor cells, was also necessary for it to be able to promote colony formation. The molecular weight of purified Meg-CSF was estimated to be 46,000 by SDS-PAGE. This molecular weight determination was very similar to the findings of Kawakita et al. (6) for Meg-CSF activity detected in the urinary extracts of patients with aplastic anemia. These investigators found two distinct peaks of activity after Sephadex G-200 gel filtration, which were estimated to have apparent mol wt of 155,000 and 76,000. When gel filtration was perform under disaggregating conditions (6 M guanidine hydrochloride), the first peak was significantly reduced and a single peak with an apparent mol wt of 45,000 was observed.
Several groups have reported that Epo is capable of stimulating megakaryocyte colony formation in vitro (5, 41 ). It appears likely that our Meg-CSF activity is distinct from Epo. Asialo-erythropoietin and native Epo have apparent mol wt on SDS-PAGE of 34,000 and 39,000, respectively (32) ; however, human Meg-CSF has an apparent mol wt of 46,000 on SDS-PAGE. In addition, our purified Meg-CSF was unable to support erythroid colony formation by normal human marrow cells. That Meg-CSF and Epo are different moieties has been previously substantiated by the fact that the ability of aplastic anemia serum to support erythroid but not megakaryocyte colony formation can be abolished by prior treatment of the serum with an antierythropoietin antisera (42) . The relationship between the purified Meg-CSF and thrombopoietin is as yet undetermined. These studies will be particularly difficult, be-cause an adequate in vitro assay system for thrombopoietin is not presently available.
The exact cellular target of Meg-CSF is not presently known. Unfractionated human marrow mononuclear cell preparations were used in the present assay system as target cells. The importance of cellular interactions in the regulation of hematopoiesis is well established (43) . Bagby and coworkers, for example, have recently shown that GM-CSA can be produced by vascular endothelial cells in response to a stimulating monokine (44) . Whether Meg-CSF directly affects the CFU-M or exerts its effect through such a marrow accessory cell pathway is yet to be determined. Whatever its exact mechanism of action might be, the biological effect of Meg-CSF appears to be rather specific in that it does not increase cloning efficiency of other progenitor cells.
Purification of human Meg-CSF from hypomegakaryocytic plasma has potential clinical significance. The presence of varying amounts of this factor in urine, plasma, and serum of patients with disorders of megakaryocytopoiesis indicates its physiological importance in the regulation of megakaryocytopoiesis. The purification of this molecule will allow a more direct analysis of the cellular and molecular events in human megakaryocytopoiesis. In addition, the feasibility of the administration of large quantities of this purified protein to patients with thrombocytopenia should be explored.
